Comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder: an open-label multicenter study

References

• World Health OrganizationDepression. Fact sheet2017 [updated February 2017]. Available from: http://www.who.int/mediacentre/factsheets/fs369/en/Accessed May 24, 2017
   Google Scholar
• American Psychiatric AssociationPractice guideline for the treatment of patients with major depressive disorder3rd ed2010 Available from: http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdfAccessed December 3, 2014
   Google Scholar
• Japanese Society of Mood DisordersTreatment guideline II: major depressive disorder, 2013 Ver. 1.12013 Available from: http://www.secretariat.ne.jp/jsmd/mood_disorder/img/130924.pdfAccessed December 3, 2014 Japanese
   Google Scholar
• RushAJWisniewskiSRZisookSIs prior course of illness relevant to acute or longer-term outcomes in depressed out-patients? A STAR*D reportPsychol Med20124261131114922008447
   PubMed Web of Science ®Google Scholar
• BauerMBschorTPfennigAWFSBP Task Force on Unipolar Depressive DisordersWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary careWorld J Biol Psychiatry2007826710417455102
   PubMed Web of Science ®Google Scholar
• AndersonIMFerrierINBaldwinRCEvidence-based guidelines for treating depressive disorders with antidepressants: a revision of the British Association for Psychopharmacology guidelinesJ Psychopharmacol200822434339618413657
   PubMed Web of Science ®Google Scholar
• PapakostasGIFavaMThaseMETreatment of SSRI-resistant depression: a meta-analysis comparing within-versus across-class switchesBiol Psychiatry200863769970417919460
   PubMed Web of Science ®Google Scholar
• Guico-PabiaCJJiangQNinanPTThaseMEClinical outcomes following switch from venlafaxine ER to desvenlafaxine in nonresponders and respondersCurr Med Res Opin20112791815182621812735
   PubMed Web of Science ®Google Scholar
• HiguchiTHongJPJungHYWatanabeYKunitomiTKamijimaKParoxetine controlled-release formulation in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled study in Japan and KoreaPsychiatry Clin Neurosci201165765566321895859
   PubMed Web of Science ®Google Scholar
• GoldenRNNemeroffCBMcSorleyPPittsCDDubéEMEfficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depressionJ Clin Psychiatry200263757758412143913
   PubMed Web of Science ®Google Scholar
• KatoMKimuraTKimuraTHaraTSafety and effectiveness of controlled-release paroxetine in routine clinical practice: results of a postmarketing surveillance study of patients with depressionNeuropsychiatr Dis Treat20151143545225759586
   PubMed Web of Science ®Google Scholar
• DeVaneCLPharmacokinetics, drug interactions, and tolerability of paroxetine and paroxetine CRPsychopharmacol Bull200337Suppl 12941
   Google Scholar
• GoldenRNEfficacy and tolerability of controlled-release paroxetinePsychopharmacol Bull200337Suppl 117618614566210
   PubMedGoogle Scholar
• RamsbergJAsseburgCHenrikssonMEffectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness modelPLoS One201278e4200322876296
   PubMed Web of Science ®Google Scholar
• KishiTMatsudaYMatsunagaSEscitalopram versus paroxetine controlled release in major depressive disorder: a randomized trialNeuropsychiatr Dis Treat20171311712528123299
   PubMed Web of Science ®Google Scholar
• MimuraCMurashigeMOdaTWatanabeYDevelopment and psychometric evaluation of a Japanese scale to assess depression severity: Himorogi self-rating depression scaleInt J Psychiatry Clin Pract2011151505522122689
   PubMed Web of Science ®Google Scholar
• MimuraCNishiokaMSatoNHasegawaRHorikoshiRWatanabeYA Japanese scale to assess anxiety severity: development and psychometric evaluationInt J Psychiatry Med2011411294521495520
   PubMed Web of Science ®Google Scholar
• HamiltonMDevelopment of a rating scale for primary depressive illnessBr J Soc Clin Psychol1967642782966080235
   PubMedGoogle Scholar
• BrussGSGruenbergAMGoldsteinRDBarberJPHamilton Anxiety Rating Scale Interview guide: joint interview and test-retest methods for interrater reliabilityPsychiatry Res19945321912027824679
   PubMed Web of Science ®Google Scholar
• GuyWECDEU assessment manual for psychopharmacology: publication ADM 76–338Clinical Global Impressions (CGI) ScaleWashington, DCDepartment of Health, Education, and Welfare1976218222
   Google Scholar
• BusnerJTargumSDThe clinical global impressions scale: applying a research tool in clinical practicePsychiatry (Edgmont)2007472837
   PubMedGoogle Scholar
• SansoneRASansoneLASSRIs: bad to the bone?Innov Clin Neurosci201297–84247
   Google Scholar
• LeeMSLeeHYKangSGVariables influencing antidepressant medication adherence for treating outpatients with depressive disordersJ Affect Disord20101231–321622119914719
   PubMed Web of Science ®Google Scholar
• JakubovskiEVarignondaALFreemantleNTaylorMJBlochMHSystematic review and meta-analysis: dose-response relationship of selective serotonin reuptake inhibitors in major depressive disorderAm J Psychiatry20161732173183
   Web of Science ®Google Scholar
• PatelMXAristaIATaylorMBarnesTRHow to compare doses of different antipsychotics: a systematic review of methodsSchizophr Res20131491–314114823845387
   PubMed Web of Science ®Google Scholar
• HayasakaYPurgatoMMagniLRDose equivalents of antidepressants: evidence-based recommendations from randomized controlled trialsJ Affect Disord201518017918425911132
   PubMed Web of Science ®Google Scholar
• BschorTKernHHensslerJBaethgeCSwitching the antidepressant after nonresponse in adults with major depression: a systematic literature search and meta-analysisJ Clin Psychiatry Epub2016126
   Web of Science ®Google Scholar
• LinEHVon KorffMKatonWThe role of the primary care physician in patients’ adherence to antidepressant therapyMed Care199533167747823648
   PubMed Web of Science ®Google Scholar
• BullSAHuXHHunkelerEMDiscontinuation of use and switching of antidepressants: influence of patient-physician communicationJAMA2002288111403140912234237
   PubMed Web of Science ®Google Scholar
• KeeneMSEaddyMTNelsonWWSarnesMWAdherence to paroxetine CR compared with paroxetine IR in a Medicare-eligible population with anxiety disordersAm J Manag Care20051112 SupplS362S36916236018
   PubMed Web of Science ®Google Scholar
• AljumahKAhmad HassaliAAlQhataniSExamining the relationship between adherence and satisfaction with antidepressant treatmentNeuropsychiatr Dis Treat2014101433143825120364
   PubMed Web of Science ®Google Scholar
• SivertsenHBjørkløfGHEngedalKSelbækGHelvikASDepression and quality of life in older persons: a reviewDement Geriatr Cogn Disord2015405–631133926360014
   PubMed Web of Science ®Google Scholar
• FavaMRushAJAlpertJEDifference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D reportAm J Psychiatry2008165334235118172020
   PubMed Web of Science ®Google Scholar
• SheehanDVEaddyMTShahMBMauchRPDifferences in total medical costs across the SSRIs for the treatment of depression and anxietyAm J Manag Care20051112 SupplS354S36116236017
   PubMed Web of Science ®Google Scholar
• Pharmaceuticals and Medical Devices AgencyDrug information of paroxetine CR 12.5 mg/25 mg Available from: http://www.info.pmda.go.jp/go/pack/1179041G1020_1_08/Accessed December 24, 2017 Japanese
   Google Scholar